Category Archives: Blog

Advances in Targeting B-Cell Maturation Antigen (BCMA) for Non-Invasive Imaging and Therapy in Multiple Myeloma

Recent advancements in the field of nuclear medicine have highlighted the significance of B-Cell Maturation Antigen (BCMA) as a pivotal target for the diagnosis and treatment of Multiple Myeloma (MM). In a groundbreaking study published in the European Journal of Nuclear Medicine and Molecular Imaging, a collaborative effort by the molecular imaging team at the First Affiliated Hospital of Jinan University and the Chinese Academy of Medical Sciences has demonstrated the efficacy of the radiolabeled antibody [89Zr]Zr-DFO-BCMAh230430 in non-invasive PET imaging of MM. This research represents a significant step forward in the development of specific immuno-PET probes targeting BCMA, which is highly expressed in malignant plasma cells.

Blog 2024-10-24

Going Nuclear: The Boom of Radiopharmaceutical Targets in 2024

In 2024, the radiopharmaceutical sector has seen a flurry of activity in mergers and acquisitions. In March, AstraZeneca announced a $2.4 billion acquisition of Fusion Pharmaceuticals, a biopharmaceutical company focused on developing next-generation radiolabeled conjugates (RDCs). In April, Novartis invested nearly $2.71 billion to partner with PeptiDream to co-develop several macrocyclic-targeted conjugate radiopharmaceuticals. In May, Novartis made […]

Blog 2024-10-18
The structure of CD74

CD73: A Potential Target in Cancer Immunotherapy

On September 25, 2024, I-Mab announced a strategic collaboration with Sanofi to develop, produce, and commercialize uliledlimab in Greater China. This partnership, valued at approximately €213 million (around 1.7 billion RMB), aims to leverage Sanofi’s expertise in oncology to accelerate the development and commercialization of uliledlimab, which is an innovative CD73 monoclonal antibody independently developed […]

Blog 2024-10-09
the structural changes and activation of ERBB-HER receptors

HER3/ERBB3: Dominating Cancer Therapy with ADCs and Beyond

On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a potentially first-in-class antibody-drug conjugate (ADC) targeting HER3, has met its primary endpoint for progression-free survival (PFS) in the Phase 3 lung cancer trial HERTHENA-Lung02. This treatment demonstrated statistically significant improvement compared to platinum-based chemotherapy combined with pemetrexed induction and pemetrexed […]

Blog 2024-09-27
Immunobiology of systemic lupus erythematosus

Who Dominates the Billion-Dollar Market for Systemic Lupus Erythematosus Treatment?

According to a blog released by market intelligence provider Future Market Insights, Inc. (FMI) on September 12 this year, the global market for systemic lupus erythematosus (SLE) drugs is showing significant growth, with surprising acceleration. FMI predicts that the SLE drug market will experience robust expansion in the coming years. In 2020, the market was […]

Blog 2024-09-25
The pathophysiological process of MM and BCMA signaling pathway

Research Progress on BCMA-Targeted Therapies in Multiple Myeloma

On August 27, 2024, Legend Biotech’s BCMA CAR-T product, Carvykti® (generic name: ciltacabtagene autoleucel injection), received approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). Previously, under Johnson & Johnson’s leadership, Carvykti had already been introduced in the United States, the European Union, […]

Blog 2024-09-12
The gene location and protein structure of TRPV1

TRPV1: An Important Target for Pain Treatment

Do you remember the temperature and touch receptor TRPV1 that made American scientists David Julius and Ardem Patapoutian accessible to the Nobel Prize in Physiology or Medicine in 2021? Transient Receptor Potential Vanilloid 1 (TRPV1) has gained significant attention in the field of pain treatment due to its potential as a therapeutic target. However, as […]

Blog , 2024-09-11

MC4R: A Niche Target in the Weight Loss Drug Market

On July 16, 2024, Dr. Roger Cone, co-founder of the preclinical biotech company Courage, published a study in The Journal of Clinical Investigation titled “Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice.” The research demonstrated the synergistic effect between GLP-1 receptor agonists (GLP1RA) and MC4R agonists, revealing that low […]

Blog , 2024-09-02

The glucagon receptor (GCGR)：A Key Target in Glucose Metabolism

On June 25, 2024, at the 2024 American Diabetes Association (ADA) Scientific Sessions, Suzhou Innovent Biologics and Eli Lilly announced the results of a Phase 3 clinical trialfor the GLP-1R x GCGR dual agonist, Mazdutide. This marks the first Phase 3 clinical trial (GLORY-1) in overweight or obese adults in China。The study’s primary results and exploratory endpoints of liver fat content were disclosed, showing that Mazdutide acts as a dual agonist for both GLP-1R and GCGR. It reduces body weight by suppressing appetite and delaying gastric emptying through GLP-1R activation, while enhancing weight loss efficacy by increasing energy expenditure via GCGR activation. Notably, Mazdutide uniquely promotes fatty acid oxidation and lipolysis in the liver through GCGR activation, thereby improving liver fat metabolism. As GCGR plays a crucial role in glucose metabolism, it has become a hot target in the development of diabetes and weight loss drugs.Let’s delve into the role of  the Glucagon Receptor (GCGR).

Blog , 2024-08-29
the structure of BCMA

Research Progress on Targeting BCMA in Autoimmune Diseases

The B cell maturation antigen (BCMA), a target that gained prominence due to its association with multiple myeloma, has recently shown significant progress in the treatment of autoimmune diseases. On May 10, 2024, a research team led by Wang Wei from the Department of Neurology at Tongji Hospital, Tongji Medical College, Huazhong University of Science […]

Blog , 2024-08-26